Šalis: Jungtinės Valstijos
kalba: anglų
Šaltinis: NLM (National Library of Medicine)
olanzapine (UNII: N7U69T4SZR) (olanzapine - UNII:N7U69T4SZR)
TYA Pharmaceuticals
olanzapine
olanzapine 20 mg
ORAL
PRESCRIPTION DRUG
Oral olanzapine is indicated for the treatment of schizophrenia. Efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. In adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial see [ Clinical Studies ( )]. 14.1 When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and hyperlipidemia. Clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see ( , )]. Warnings and Precautions 5.55.6 Oral olanzapine is indicated for acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment o
NDC:64725-0265-1 in a BOX of 30 TABLET, ORALLY DISINTEGRATINGS Olanzapine orally disintegrating tablets 5 mg are yellow-colored, capsule-shaped tablets, flat on one side and concave on the other side, embossed with R-262 on the flat side and plain on the concave side and are supplied in bottles of 30, carton of 10 packs containing 10 tablets each, carton of 30 packs containing 1 tablet each and carton of 3 packs containing 10 tablets each. Bottles of 30 NDC 55111-262-30 Carton of 10 packs (NDC 55111-262-78), each pack containing 10 tablets (55111-262-79) Carton of 30 packs (NDC 55111-262-31), each pack containing 1 tablet (55111-262-11) Carton of 3 packs (NDC 55111-262-81), each pack containing 10 tablets (55111-262-79) Olanzapine orally disintegrating tablets 10 mg are yellow-colored, capsule-shaped tablets, flat on one side and concave on the other side, embossed with R-263 on the flat side and plain on the concave side and are supplied in bottles of 30, carton of 10 packs containing 10 tablets each, carton of 30 packs containing 1 tablet each and carton of 3 packs containing 10 tablets each. Bottles of 30 NDC 55111-263-30 Carton of 10 packs (NDC 55111-263-78), each pack containing 10 tablets (55111-263-79) Carton of 30 packs (NDC 55111-263-31), each pack containing 1 tablet (55111-263-11) Carton of 3 packs (NDC 55111-263-81), each pack containing 10 tablets (55111-263-79) Olanzapine orally disintegrating tablets 15 mg are yellow-colored, capsule-shaped tablets, flat on one side and concave on the other side, embossed with R-264 on the flat side and plain on the concave side and are supplied in bottles of 30, carton of 10 packs containing 10 tablets each, carton of 30 packs containing 1 tablet each and carton of 3 packs containing 10 tablets each. Bottles of 30 NDC 55111-264-30 Carton of 10 packs (NDC 55111-264-78), each pack containing 10 tablets (55111-264-79) Carton of 30 packs (NDC 55111-264-31), each pack containing 1 tablet (55111-264-11) Carton of 3 packs (NDC 55111-264-81), each pack containing 10 tablets (55111-264-79) Olanzapine orally disintegrating tablets 20 mg are yellow-colored, capsule-shaped tablets, flat on one side and concave on the other side, embossed with R-265 on the flat side and plain on the concave side and are supplied in bottles of 30, carton of 10 packs containing 10 tablets each, carton of 30 packs containing 1 tablet each and carton of 3 packs containing 10 tablets each. Bottles of 30 NDC 55111-265-30 Carton of 10 packs (NDC 55111-265-78), each pack containing 10 tablets (55111-265-79) Carton of 30 packs (NDC 55111-265-31), each pack containing 1 tablet (55111-265-11) Carton of 3 packs (NDC 55111-265-81), each pack containing 10 tablets (55111-265-79) Store olanzapine orally disintegrating tablets at controlled room temperature, 20° to 25°C (68° to 77°F) [see USP]. The USP defines controlled room temperature as a temperature maintained thermostatically that encompasses the usual and customary working environment of 20° to 25°C (68° to 77°F); that results in a mean kinetic temperature calculated to be not more than 25°C; and that allows for excursions between 15° and 30°C (59° and 86°F) that are experienced in pharmacies, hospitals, and warehouses. Protect olanzapine orally disintegrating tablets from light and moisture.
Abbreviated New Drug Application
OLANZAPINE- OLANZAPINE TABLET, ORALLY DISINTEGRATING TYA Pharmaceuticals ---------- Medication Guide Olanzapine Orally Disintegrating Tablets Read the Medication Guide that comes with olanzapine orally disintegrating tablets before you start taking them and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment. Talk with your doctor or pharmacist if there is something you do not understand or you want to learn more about olanzapine orally disintegrating tablets. WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT OLANZAPINE ORALLY DISINTEGRATING TABLETS? Olanzapine orally disintegrating tablets may cause serious side effects, including: 1. Increased risk of death in elderly people who are confused, have memory loss and have lost touch with reality (dementia-related psychosis). 2. High blood sugar (hyperglycemia). 3. High fat levels in your blood (increased cholesterol and triglycerides), especially in teenagers age 13 to 17. 4. Weight gain, especially in teenagers age 13 to 17. These serious side effects are described below. Olanzapine orally disintegrating tablets are not approved for treating psychosis in elderly people with dementia. 1. Increased risk of death in elderly people who are confused, have memory loss and have lost touch with reality (dementia-related psychosis). High blood sugar can happen if you have diabetes already or if you have never had diabetes. High blood sugar could lead to: 2. High blood sugar (hyperglycemia). • a build up of acid in your blood due to ketones (ketoacidosis) • coma • death Your doctor should do tests to check your blood sugar before you start taking olanzapine orally disintegrating tablets and during treatment. In people who do not have diabetes, sometimes high blood sugar goes away when olanzapine orally disintegrating tablets are stopped. People with diabetes and some people who did not have diabetes before taking olanzapine orally disintegra Perskaitykite visą dokumentą
OLANZAPINE- OLANZAPINE TABLET, ORALLY DISINTEGRATING TYA PHARMACEUTICALS ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE OLANZAPINE ORALLY DISINTEGRATING TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR OLANZAPINE ORALLY DISINTEGRATING TABLETS. OLANZAPINE ORALLY DISINTEGRATING TABLETS FOR ORAL USE INITIAL U.S. APPROVAL: 1996 WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ • ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS TREATED WITH ANTIPSYCHOTIC DRUGS ARE AT AN INCREASED RISK OF DEATH. OLANZAPINE IS NOT APPROVED FOR THE TREATMENT OF PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS ( , 5.1, ). 5.1417.2 WHEN USING OLANZAPINE AND FLUOXETINE IN COMBINATION, ALSO REFER TO THE BOXED WARNING SECTION OF THE PACKAGE INSERT FOR SYMBYAX. RECENT MAJOR CHANGES Indications and Usage, Olanzapine and Fluoxetine in Combination: Depressive Episodes Associated with Bipolar I Disorder MM/YYYY (1.5) Dosage and Administration, Olanzapine and Fluoxetine in Combination: Depressive Episodes Associated with Bipolar I Disorder MM/YYYY (2.5) INDICATIONS AND USAGE Olanzapine is an atypical antipsychotic indicated: _As oral formulation for the:_ • Treatment of schizophrenia. ( ) 1.1 Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. ( ) 14.1 Adolescents (ages 13 to 17): Efficacy was established in one 6week trial in patients with schizophrenia . The increased potential (in adolescents compared with adults) for weight gain and hyperlipidemia may lead clinicians to consider prescribing other drugs first in adolescents. (14.1)(1.1) • Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. ( ) 1.2 Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disord Perskaitykite visą dokumentą